Results 291 to 300 of about 291,899 (358)

Long‐Term Safety and Efficacy of Repeat Treatments with DaxibotulinumtoxinA in Cervical Dystonia: Results from the ASPEN‐Open‐Label Study

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background DaxibotulinumtoxinA (DAXI), a novel botulinum neurotoxin (BoNT) formulation, was shown to be safe, effective, and long‐lasting in the treatment of cervical dystonia (CD) over one treatment cycle in the phase 3, randomized, placebo‐controlled ASPEN‐1 trial.
Peter McAllister, Atul T. Patel, Marta Banach, Aaron Ellenbogen, Jaroslaw Slawek, Sebastian Paus, Hyder A. Jinnah, Virgilio Evidente, Todd M. Gross, Rashid Kazerooni, Conor J. Gallagher, David A. Hollander   +11 more
wiley   +1 more source

The Persistence of Dopamine Dysregulation Syndrome after Pallidal Deep Brain Stimulation in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Dopamine dysregulation syndrome (DDS) is a debilitating complication of Parkinson's disease (PD) dopamine replacement therapy (DRT) in which patients pathologically and/or compulsively use dopaminergic drugs to treat motor symptoms. Studies examining DDS outcomes following deep brain stimulation (DBS) are limited and have focused on
Natalie David, Stewart A. Factor, Richa Tripathi, Lenora Higginbotham   +3 more
wiley   +1 more source

Serum Malondialdehyde Levels Decreased Along with the Alleviating Effects of Marrubium Parviflorum on Morphine Withdrawal Syndrome in Rats. [PDF]

Arch Razi Inst
Fekri K, Hooshangi F, Parvizpur A, Charkhpour M, Hamedeyazdan S.   +4 more
europepmc   +1 more source

Real-world analysis on the use of gamma-hydroxybutyric acid for alcohol withdrawal syndrome in hospitalized patients with diagnosis of cirrhosis. [PDF]

Intern Emerg Med
Salomoni M, Missanelli A, Crescioli G, Lanzi C, Totti A, Losso L, Gitto S, Bonaiuti R, Vannacci A, Lombardi N, Mannaioni G.   +10 more
europepmc   +1 more source

Subjective Well‐Being and Its Predictors in Parkinson's Disease and Dystonia: A Comparative Study

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Quality of life (QoL) is a commonly used outcome measure in people with chronic neurological diseases (CND). As valuable as QoL is, it does not take into account aspects of subjective well‐being (SWB) such as subjective happiness, meaning in life, life satisfaction and hope; all constructs that are considered central to well‐being ...
Suzette Shahmoon, Dejan Georgiev, Paul Jarman, Kailash Bhatia, Patricia Limousin, Marjan Jahanshahi   +5 more
wiley   +1 more source

ZSCAN25 methylation predicts seizures and severe alcohol withdrawal syndrome. [PDF]

Epigenetics
Andersen A, Milefchik E, Papworth E, Penaluna B, Dawes K, Moody J, Weeks G, Froehlich E, deBlois K, Long JD, Philibert R.   +10 more
europepmc   +1 more source

Maternal opioid use during pregnancy and the risk of neonatal opioid withdrawal syndrome in the offspring. [PDF]

Acta Obstet Gynecol Scand
Kristensen AW, Vestermark V, Kjærbye-Thygesen A, Eckhardt MC, Kesmodel US.   +4 more
europepmc   +1 more source

Erythematous Papules and Plaques in an Infant Receiving Glucagon Therapy

JEADV Clinical Practice, EarlyView.
Sara Al Janahi, Alya Al‐Ali, Meera Al Adawi, Yusra S. Al Ali, Harish Bangalore   +4 more
wiley   +1 more source

Prevalence and Predictors of Non-Benzodiazepine Use in Patients with Alcohol Withdrawal Syndrome in United States Emergency Departments - a cross-sectional study. [PDF]

Innov Pharm
Zakhary K, Bruno S, Myatt CA, Perera V, Saleh K, Smearman JA, Yuzwa MM, Soric MM, Zampino S.   +8 more
europepmc   +1 more source